Industry
Biotechnology
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 29, 2024 | 10:42 am
Portfolio Pulse from Benzinga Newsdesk
May 24, 2024 | 8:49 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 10:48 am
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 10:35 am
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 5:03 pm
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 11:33 am
Portfolio Pulse from Benzinga Newsdesk
March 27, 2024 | 10:52 am
Portfolio Pulse from Benzinga Newsdesk
March 27, 2024 | 10:51 am
Portfolio Pulse from Benzinga Insights
March 27, 2024 | 9:02 am
Portfolio Pulse from Benzinga Insights
March 26, 2024 | 5:00 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.